ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions
View by Date

Sunday, November 8, 2020

9:00AM-11:00AM
Abstract Number: 1413
An Imbalance Between Regulatory and Inflammatory T Cell Subsets Distinguishes Systemic Autoimmune Rheumatic Disease Patients from Asymptomatic ANA+ Individuals
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 1240
An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis
RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs
9:00AM-11:00AM
Abstract Number: 1203
Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis
RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs
9:00AM-11:00AM
Abstract Number: 1333
Ankylosing Spondylitis Patients at Risk of Developing Aortic Valve Regurgitation, Need for Mandatory Echocardiography?
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities
9:00AM-11:00AM
Abstract Number: 1016
Annual Cardiac or Orthopedic Procedure Volume in Gout versus Rheumatoid Arthritis: A National Time-trends Study
Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease
9:00AM-11:00AM
Abstract Number: 1073
Anti Melanoma Differentiation-associated Protein Gene 5 Antibody Titer Monitoring Is a Useful Indicator for Early Detection of Recurrence in Rapidly Progressive Interstitial Lung Disease Associated with Dermatomyositis
Muscle Biology, Myositis & Myopathies Poster
9:00AM-11:00AM
Abstract Number: 1098
Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis
Muscle Biology, Myositis & Myopathies Poster
9:00AM-11:00AM
Abstract Number: 1427
Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) – An 18 Month Follow-up Study as a Steroid Sparing Therapeutic Approach
Vasculitis – ANCA-Associated Poster
9:00AM-11:00AM
Abstract Number: 1076
Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom
Muscle Biology, Myositis & Myopathies Poster
9:00AM-11:00AM
Abstract Number: 1059
Anti-mitochondrial Autoantibodies Are Associated with Cardiomyopathy, Dysphagia, and Features of More Severe Disease in Adult-onset Myositis
Muscle Biology, Myositis & Myopathies Poster
9:00AM-11:00AM
Abstract Number: 1064
Anti-SMN Autoantibodies Are Associated with Systemic Sclerosis Small Bowel Involvement in anti-U1RNP Positive Autoimmune Myositis
Muscle Biology, Myositis & Myopathies Poster
9:00AM-11:00AM
Abstract Number: 1067
Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease
Muscle Biology, Myositis & Myopathies Poster
9:00AM-11:00AM
Abstract Number: 1261
Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities
9:00AM-11:00AM
Abstract Number: 1284
Application of a Novel Method for Determination of Muscle Mass Relative to Fat Mass in Women with Systemic Lupus Erythematosus and Association with Disability
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities
9:00AM-11:00AM
Abstract Number: 1320
Are Coping Strategies, Anxiety and Depression Associated with Daily Physical Activity in Patient with Axial SpA?
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 37
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology